Historical biib News Stories
Biogen Stock Slides After JP Morgan Week Outflows.
Biogen (BIIB) saw modest share weakness amid broad biotech fund outflows following the J.P. Morgan Healthcare Conference. With analysts largely neutral, lower passive demand after Nasdaq‑100 exclusion, and fresh Alzheimer’s competition highlighted by Novartis’s $1.7B SciNeuro deal, near‑term upside appears limited absent a clear pipeline or corporate catalyst.
Biogen Rally: CHMP OKs High‑Dose Nusinersen Surge!
Biogen stock jumped to a 52-week high after the EMA's CHMP issued a positive opinion for a high-dose nusinersen regimen. The regulatory catalyst, combined with strong trading days in early January, has driven measurable investor interest and could expand Spinraza’s EU positioning pending the European Commission decision.
Biogen: CHMP Nod for Nusinersen; LEQEMBI Wins Data
Biogen received a positive CHMP opinion for a high-dose nusinersen regimen and reported CTAD data strengthening LEQEMBI’s pharmacodynamic profile. Both developments offer near-term regulatory and scientific catalysts for BIIB shares, though analyst coverage and upside remain modest.
Biogen Dropped from Nasdaq-100; HSBC Downgrade Now
Biogen was removed from the Nasdaq‑100 and received an HSBC downgrade last week, triggering index-driven selling, reduced liquidity, and renewed analyst scrutiny. This article explains the immediate market mechanics, investor implications, and key items to watch next for BIIB.
Biogen Removed From Nasdaq-100; ETF Selloff Looms
Biogen (BIIB) will be dropped from the Nasdaq‑100 before trading on Dec. 22, 2025, triggering likely passive selling by index-tracking funds. Recent volume spikes and price weakness contrast with improved technical momentum and a reduced competitive overhang after a rival Alzheimer’s candidate failed Phase 3.
Biogen Slides: 3-Day Drop, Alzheimer Lead Grows Up
Biogen (BIIB) slipped for a third straight day amid light volume even as competitor setbacks in Alzheimer’s research reinforced Biogen’s Leqembi positioning. Recent coverage shows a near-term pullback in the shares, limited reaction across biotech to a Fed rate cut, and concrete competitive developments — all tangible drivers for BIIB investors to evaluate.
Biogen Surges After Dayra Deal, Leqembi sBLA Push.
Biogen (BIIB) climbed after a research collaboration with Dayra Therapeutics and a rolling sBLA submission for Leqembi IQLIK. These concrete developments—$50M upfront, subcutaneous dosing pathway, and recent stock moves—offer clear near-term catalysts.
Biogen Rally: Dayra Pact, Leqembi, Q3 Beat, NovoRx
Biogen (BIIB) climbed after a strategic Dayra Therapeutics collaboration, a rival Alzheimer’s setback from Novo Nordisk, and a stronger-than-expected Q3. Upcoming CTAD presentations and real-world Leqembi data offer additional near-term catalysts.
Biogen Strengthens With ThecaFlex Deal, CHMP Win!!
Biogen (BIIB) saw concrete catalysts last week: completing the ThecaFlex acquisition and securing a positive CHMP opinion for high‑dose nusinersen. Stock moves and analyst updates reflect renewed investor focus on delivery tech and regulatory progress.
Biogen's Leqembi Win, Vanqua Deal, Q3 Headwinds Up
Biogen (BIIB) saw three clear catalysts this week: Health Canada approved lecanemab (LEQEMBI®) for early Alzheimer’s, Biogen inked an exclusive deal with Vanqua Bio for a preclinical oral C5aR1 antagonist, and Q3 results prompted a trimmed full-year earnings outlook. These developments expand commercial reach and pipeline diversity but introduce near-term financial pressure that investors should weigh.
Biogen Beats Q3 but Cuts Guidance - Stock Rebounds
Biogen reported better-than-expected Q3 results but trimmed full-year guidance, announced a strategic licensing deal, and saw analyst upgrades—driving a rebound in BIIB shares amid mixed near-term signals.